Why All Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Should Have Their Tumors Tested for EGFR and ALK Abnormalities

The anaplastic lymphoma kinase (ALK) fusion oncogene and the epidermal growth factor receptor (EGFR) represent molecular targets in a subset of non-small cell lung cancers (NSCLCs). NSCLC accounts for nearly 85 % of all lung cancers with 7 % of patients harbouring an abnormal ALK gene and as many as 17 % of patients positive for EGFR. Treatments targeting EGFR (erlotinib) and ALK (crizotinib) have demonstrated impressive antitumor activity in the majority of patients  harbouring these oncogenes however, the cancers typically develop resistance to these drugs within one year. AP26113 is dual inhibitor of ALK and EGFR designed to overcome resistance to crizotinib and erlotinib. Preclinical data has shown that AP26113 is highly active against crizotinib and erlotinib resistant cancer cells both in-vitro and in-vivo. I like this AP26113 because it is a highly selective drug that targets treatment resistant tumors by attacking two different oncogenic pathways. The following link is to an upcoming AP26113 clinical trial for patients with NSCLC.
Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113.

Speak Your Mind